Seshadri R, Bagli-Vania N D, Suraiya J N, Sheth N A
Endocrinology Unit, Tata Memorial Hospital, Parel, Bombay, India.
J Cancer Res Clin Oncol. 1990;116(3):271-4. doi: 10.1007/BF01612902.
Since there are controversial reports in the literature on 16 alpha-hydroxylase activity in human breast tumors, we have studied this enzyme activity in "normal", benign and malignant breast tissues by measuring the conversion of estradiol to estriol. Whereas 8 out of 14 (58%) malignant tumors showed positive activity, none of the other tissues had any detectable 16 alpha-hydroxylase activity. These preliminary results, when combined with reports in the literature on animal and human tissues, appear to indicate that more extensive studies on this enzyme could be useful as it could be an additional metabolic marker in human breast cancer.
由于文献中关于人类乳腺肿瘤中16α-羟化酶活性的报道存在争议,我们通过测量雌二醇向雌三醇的转化,研究了“正常”、良性和恶性乳腺组织中的这种酶活性。14个恶性肿瘤中有8个(58%)显示出阳性活性,而其他组织均未检测到任何16α-羟化酶活性。这些初步结果与文献中关于动物和人类组织的报道相结合,似乎表明对这种酶进行更广泛的研究可能会有所帮助,因为它可能是人类乳腺癌中的一种额外代谢标志物。